We power outstanding life science companies
At Shaman Pharma, we're dedicated to confronting Global, Urgent, and Massive (GUM) problems.
With a strategic emphasis on the urgency of global crises such as mental health, antimicrobial resistance, and opioid use recovery, we challenge ourselves to be innovative disruptors and game-changers in the healthcare landscape through our unique Venture Studio model - Awakening Innovation.
Welcome to the frontlines of therapeutic innovation. Welcome to Shaman Pharma.
Our model: Awakening Innovation
Our model thrives on identifying, nurturing, and commercializing life science innovations that address these GUM issues.
We are more than just a pharmaceutical company - we are a collective of scientists, strategists, and visionaries pushing the boundaries of therapeutic discovery and development.
One of our significant achievements is the first-ever authorization from Health Canada's Special Access Program for MDMA use outside a clinical trial. This milestone is a testament to our pioneering spirit and commitment to accelerating change in healthcare.
In a world where innovation is key, we turn tomorrow's scientific breakthroughs into today's health solutions.
The future of sustainable investments
We are not just creating transformative healthcare solutions; we are also shaping the future of sustainable investments.
Through our venture studio model, we aim to create a stream of publicly-trading companies pushing the boundaries of life sciences. By marrying biotech innovation with business acumen, we are accelerating the pathway from lab bench to market, translating cutting-edge science into tangible health outcomes
Investors have the opportunity to be a part of this journey - a journey that redefines pharmaceutical paradigms, drives substantial returns, and brings hope to those grappling with global health crises.
We turn breakthroughs into benefits, solutions into sustainable investments, and potential into reality.
Press Releases, Articles & Announcements
SUBSCRIBE TO SHAMAN
Keep informed with the Shaman Pharma newsletter